Very hot-offering Inhibitors

Rock and roll and roll inhibitor

Y-27632 dihydrochloride

Y-27632 dihydrochloride is truly a specific ROCK1 (p160ROCK) inhibitor with Ki of 140 nM, uncovers>200-fold selectivity over other kinases, that come with PKC, camp out out-centered healthful protein kinase, MLCK and PAK.

Relevant Products: Thiazovivin, Fasudil (HA-1077) HCl

GSK-3 inhibitor


CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, and that is certainly certainly a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM capacity to specific GSK-3 as well as its nearest homologs Cdc2 and ERK2.

Linked Products: SB216763 , CHIR-98014

Proteasome Inhibitor


MG-132 is unquestionably an inhibitor of proteasome with IC50 of 100 nM, and likewise inhibits calpain with IC50 of 1.2 μM.

Connected Goods: Carfilzomib (PR-171) , ONX-0914 (PR-957)

HDAC Inhibitor

Romidepsin  (FK228, Depsipeptide)

Romidepsin  (FK228, depsipeptide) could be a highly effective HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM, correspondingly.

Affixed Goods: Entinostat (MS-275) , Trichostatin A (TSA)

Akt Inhibitor

MK-2206 2HCl

MK-2206 2HCl is actually a highly a number of inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM, correspondingly no inhibitory actions against 250 other protein kinases noticed. Cycle 2.

Associated Merchandise: AZD5363 , GDC-0068

Raf Inhibitor


Vemurafenib (PLX4032, RG7204) is truly a particular and powerful inhibitor of B-RafV600E with IC50 of 31 nM.

Important Goods: Sorafenib Tosylate , PLX-4720

Goods and services Catalog

Product Range

32 varieties of aspect libraries for major throughput analyzing and information confirmation.

Investigation Locations



JAK/STAT Signaling

Tyrosine Kinase/Adaptors

PI3K/Akt/mTOR Signaling

MAPK Signaling





DNA Cause damage to/DNA Restoration

Tel: 857-239-0968 Fax: 857-239-8801

E email: marketing and

Involve: One Boston Spot, Package 2600, Boston, MA 02108.

A single Boston Position, Offer 2600, Boston, Massachusetts, 02108

Leave a Reply

Your email address will not be published. Required fields are marked *